Patents by Inventor Cornelia Irl

Cornelia Irl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20230226179
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: January 4, 2023
    Publication date: July 20, 2023
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20210052728
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: May 13, 2020
    Publication date: February 25, 2021
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20180344847
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20170143826
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 25, 2017
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20160279241
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: June 16, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Anti-angiogenesis therapy for the treatment of ovarian cancer
    Patent number: 8778340
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: July 15, 2014
    Assignee: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20140178371
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: January 16, 2014
    Publication date: June 26, 2014
    Applicant: GENENTECH, INC.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20110206662
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 25, 2011
    Applicant: GENENTECH, INC.
    Inventors: Jakob Dupont, Cornelia Irl